145 related articles for article (PubMed ID: 35639145)
1. Development and validation of a computed tomography-based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer.
He L; Li ZH; Yan LX; Chen X; Sanduleanu S; Zhong WZ; Lambin P; Ye ZX; Sun YS; Liu YL; Qu JR; Wu L; Tu CL; Scrivener M; Pieters T; Coche E; Yang Q; Yang M; Liang CH; Huang YQ; Liu ZY
Eur Radiol; 2022 Dec; 32(12):8726-8736. PubMed ID: 35639145
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell Lung Cancer.
He L; Huang Y; Chen X; Huang X; Wang H; Zhang Y; Liang C; Li Z; Yan L; Liu Z
Front Immunol; 2022; 13():835630. PubMed ID: 35401554
[TBL] [Abstract][Full Text] [Related]
3. Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients.
Trentini F; Mazzaschi G; Milanese G; Pavone C; Madeddu D; Gnetti L; Frati C; Lorusso B; Lagrasta CAM; Minari R; Ampollini L; Ledda RE; Silva M; Sverzellati N; Quaini F; Roti G; Tiseo M
Tumori; 2022 Feb; 108(1):86-92. PubMed ID: 33730957
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
5. Automated whole-slide images assessment of immune infiltration in resected non-small-cell lung cancer: towards better risk-stratification.
Lin H; Pan X; Feng Z; Yan L; Hua J; Liang Y; Han C; Xu Z; Wang Y; Wu L; Cui Y; Huang X; Shi Z; Chen X; Chen X; Zhang Q; Liang C; Zhao K; Li Z; Liu Z
J Transl Med; 2022 Jun; 20(1):261. PubMed ID: 35672787
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC.
Lee J; Cui Y; Sun X; Li B; Wu J; Li D; Gensheimer MF; Loo BW; Diehn M; Li R
Eur Radiol; 2018 Feb; 28(2):736-746. PubMed ID: 28786009
[TBL] [Abstract][Full Text] [Related]
7. A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer.
Lee J; Li B; Cui Y; Sun X; Wu J; Zhu H; Yu J; Gensheimer MF; Loo BW; Diehn M; Li R
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1098-1106. PubMed ID: 29439884
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC.
Mazzaschi G; Milanese G; Pagano P; Madeddu D; Gnetti L; Trentini F; Falco A; Frati C; Lorusso B; Lagrasta C; Minari R; Ampollini L; Silva M; Sverzellati N; Quaini F; Roti G; Tiseo M
Lung Cancer; 2020 Jun; 144():30-39. PubMed ID: 32361033
[TBL] [Abstract][Full Text] [Related]
10. Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer.
Bocchialini G; Lagrasta C; Madeddu D; Mazzaschi G; Marturano D; Sogni F; Silini EM; Gnetti L; Becchi G; Rusca M; Carbognani P; Ventura L; Braggio C; Tiseo M; Quaini F; Ampollini L
Eur J Cardiothorac Surg; 2020 Sep; 58(3):619-628. PubMed ID: 32267920
[TBL] [Abstract][Full Text] [Related]
11. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
12. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
14. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
16. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
17. Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study.
Aragaki M; Kato T; Fujiwara-Kuroda A; Hida Y; Kaga K; Wakasa S
J Cardiothorac Surg; 2020 Aug; 15(1):229. PubMed ID: 32859238
[TBL] [Abstract][Full Text] [Related]
18. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
[TBL] [Abstract][Full Text] [Related]
19. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
